Camp4 Therapeutics Corp
Camp4 Therapeutics Corp is listed today as CAMP4 Therapeutics Corporation: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2022 | $100 M | No. 3 | $50 to $250 million | equity | SEC | |
| Mar 2021 | $45 M | No. 2 | $10 to $50 million | equity | SEC | |
| Apr 2018 | $34 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company CAMP4 Therapeutics Corporation, its revenue in fiscal 2025 came from these business segments: R&D $3.50 million (100%).
Annual report (SEC XBRL) · Dec 2025
Camp4 Therapeutics Corp chose not to state its revenue in its newest notice of a funding round (Jun 2022).
SEC Form D · Jun 2022
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2022
Products and services#
No products or services of Camp4 Therapeutics Corp are on record.
Investors#
18 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| 5AM Opportunities II (GP), LLC | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| 5AM Opportunities II, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| 5AM Partners VI, LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| 5AM Ventures VI, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| AH Bio Fund I, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| AH Equity Partners Bio I, L.L.C. | Private equity | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Enavate Sciences GP, LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Everest Aggregator, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Josh Mandel-Brehm | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2024) | SEC Form 3 |
| Northpond Ventures GP II, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Northpond Ventures GP, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Northpond Ventures II, LP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Northpond Ventures, LP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Polaris Entrepreneurs' Fund VII, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Polaris Management Co. VII, L.L.C. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Polaris Partners VII, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Richard A. Young | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2024) | SEC Form 3 |
| Steven H. Holtzman | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2024) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 16 investors.
Largest shareholders today
Institutions holding CAMP4 Therapeutics Corporation shares, as of Sep 30, 2026.
- Janus Henderson Group Ltd.$31 M12.41%
- Vivo Capital, LLC$23 M8.90%
- 5AM Venture Management, LLC$21 M8.41%
- FMR LLC$20 M7.82%
- Adage Capital Partners GP, L.L.C.$17 M6.68%
- Trails Edge Capital Partners, LP$15 M5.78%
- Stonepine Capital Management, LLC$11 M4.44%
- Balyasny Asset Management L.P.$10 M3.84%
- Vanguard Capital Management LLC$9 M3.42%
- a16z Capital Management, L.L.C.$9 M3.39%
- BlackRock, Inc.$8 M3.19%
- HarbourVest Partners LLC$5 M2.03%
- Enavate Sciences GP, LLC$4 M1.66%
- Ikarian Capital, LLC$4 M1.45%
- Geode Capital Management, LLC$4 M1.44%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Alfica Sehgal | Executive officer | Jun 2022 |
| Ann Barbier | Executive officer | Jun 2022 |
| Caleb Moore | Executive officer | Jun 2022 |
| David Bumcrot | Executive officer | Jun 2022 |
| Josh Mandel-Brehm | Executive officer | Jun 2022 |
| Kelly Gold | Executive officer | Jun 2022 |
| Michelle Gates | Executive officer | Jun 2022 |
| Amir Nashat | Director | Jun 2022 |
| Andrew J. Schwab | Director | Jun 2022 |
| James J. Boylan | Director | Jun 2022 |
| Jorge Conde | Director | Jun 2022 |
| Josh Mandel-Brehm | Director | Jun 2022 |
| Michael Higgins | Director | Jun 2022 |
| Paula Ragan | Director | Jun 2022 |
| Ravi I. Thadhani | Director | Jun 2022 |
| Richard Young | Director | Jun 2022 |
| Shaan I. Gandhi | Director | Jun 2022 |
| Steve Holtzman | Director | Jun 2022 |
| Andy Schwab | Director | Oct 2021 |
| Ravi Thadhani | Director | Oct 2021 |
| Shaan Gandhi | Director | Oct 2021 |
Went public since 2024. Its SEC number is that of a company listed on a stock exchange.